Western biopharma companies are seeking new drug candidates in China to offset a patent cliff in the early 2030s, when patents on top-selling drugs are set to expire
Agree
Disagree
Overview
Debates
Related claims
Topics
Sources
From the article
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Also in
Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
5
52c7ae14
Article
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
0
5
52c7ae14
Article
Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
0